Measuring drug efficacy with a more human model
New platforms to better understanding the complexity of drug efficacy across a diverse genetic and spontaneous environment would be a powerful asset in drug discovery.
“Clinical efficacy in a dish” refers to the use of lab-grown human iPSC derived cells (in single, co-culture or 3D form) to test the effectiveness of a potential treatment in a controlled, laboratory setting. This approach allows scientists to study the effects of drugs or therapies on cells or tissue that closely resemble those found in the human body, which can provide a more accurate prediction of how the treatment will perform in clinical trials. This approach is a powerful tool for drug discovery, as it may provide a more efficient and cost-effective way to test the efficacy of potential treatments before they are tested in human clinical trials.
Bouhaddou et al. reported that reliably predicting in vivo efficacy from in vitro data would facilitate drug development by reducing animal usage and guiding drug dosing in human clinical trials. They demonstrated that only a change in a single parameter-the one controlling intrinsic cell/tumor growth in the absence of drug-was needed to scale the model from the in vitro to in vivo setting.